The role of CD200-CD200R in tumor immune evasion

Journal of Theoretical Biology

Volumn 328, Issue , 2013, Pages 65-76

  Liao, Kang Ling ^a   Bai, Xue Feng ^b   Friedman, Avner ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

CD200R; Interleukin 10; Interleukin 12; Macrophages; Tumor cells

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12;

CELL ORGANELLE; COMPLEXITY; IMMUNE SYSTEM; MEMBRANE; NUMERICAL MODEL; PROTEIN; TUMOR;

ALGORITHM; ARTICLE; BINDING AFFINITY; DOWN REGULATION; IMMUNOREGULATION; M1 MACROPHAGE; M2 MACROPHAGE; MACROPHAGE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIMULATION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MACROPHAGES; MODELS, IMMUNOLOGICAL; NEOPLASM PROTEINS; NEOPLASMS; RECEPTORS, CELL SURFACE; TUMOR ESCAPE;

EID: 84876435186     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2013.03.017     Document Type: Article

References (70)

1. Abe R., Donnelly S.C., Peng T., Bucala R., Metz C.N. Peripheral blood fibrocytes. differentiation pathway and migration to wound sites. J. Immunol. 2001, 166:7556-7562.
2. Allavena P., Paganin C., Zhou D., Bianchi G., Sozzani S., Mantovani A. Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium. Blood 1994, 84:2261-2268.
3. Asadullah K., Sterry W., Volk H.D. Interleukin-10 therapy-review of a new approach. Pharmacol. Rev. 2003, 55:241-269.
4. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets. cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
5. Breward C.J.W., Byrne H.M., Lewis C.E. Modeling the interactions between tumor cells and a blood vessel in a microenvironment within a vascular tumor. Eur. J. Appl. Math. 2001, 12:529-556.
6. Brewer G., Saccani S., Sarkar S., Lewis A., Pestka S. Increased interleukin-10 mRNA stability in melanoma cells is associated with decreased levels of A+U-Rich element binding factor AUK1. J. Interf. Cytok. Res. 2003, 23:553-564.
7. Butterworth A.E., Cater D.B. Effect of lysolecithin on oxygen uptake of tumor cells polymorphonuclear leucocytes lymphocytes and macrophages in vitro. Br. J. Cancer 1967, 21:373-389.
8. Cameron C.M., Barrett J.W., Liu L., Lucas A.R., McFadden G. Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. J. Virol. 2005, 79:6052-6067.
9. Casciari J.J., Sotirchos S.V., Sutherland R.M. Glucose diffusivity in multicellular tumor spheroids. Cancer Res. 1988, 48:3905-3909.
10. Chen Y., Cairns R., Papandreou I., Koong A., Denko N.C. Oxygen consumption can regulate the growth of tumors. a new perspective on the warburg effect. PLoS ONE 2009, 4:e7033.
11. Chen D., Roda J.M., Marsh C.B., Eubank T.D., Friedman A. Hypoxia inducible factors mediate the inhibition of cancer by GM-CSF. a mathematical model. Bull. Math. Biol. 2012, 17. http://dx.doi.org/10.1007/s11538-012-9776-3.
12. D'Andrea A., Aste-Amezaga M., Valiante N.M., Ma X., Kubin M., Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon γ-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exp. Med. 1993, 178:1041-1048.
13. Day J., Friedman A., Schlesinger L.S. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc. Nat. Acad. Sci. 2008, 106:11246-11251.
14. DiLeo M.V., Kellum J.A., Federspiel W.J. A simple mathematical model of cytokine capture using a hemoadsorption device. Ann. Biomed. Eng. 2009, 37:222-229.
15. Eubank T.D., Roberts R., Galloway M., Wang Y., Cohn D.E., Marsh C.B. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Immunity 2004, 21:831-842.
16. Eubank T.D., Roberts R.D., Khan M., Curry J.M., Nuovo G.J., Kuppusamy P., Marsh C.B. Granulocyte macrophage colony-stimulating factor inhibits breast growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res. 2009, 69:2133-2140.
17. Freeman B.J., Roberts M.S., Vogler C.A., Nicholes A., Hofling A.A., Sands M.S. Behavior and therapeutic efficacy of β-glucuronidase-positive mononuclear phagocytes in murine model of mucopolysaccharidosis type VII. Blood 1999, 94:2142-2150.
18. Friedman A., Turner J., Szomolay B. A model on the influence of age on immunity to infection with Mycobacterium tuberculosis. Exp. Gerontol. 2008, 43:275-285.
19. Youn B.S., Sen A., Behie L.A., Girgis-Gabardo A., Hassell J.A. Scale-up of breast cancer stem cell aggregate cultures to suspension bioreactors. Biotechnol. Prog. 2006, 22:801-810.
20. Gabhann F.M., Popel A.S. Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H153-H164.
21. Gabrilovich D.I., Rosenberg S.O., Bronte V. Coordinated regulation of myeloid cells by tumors. Nat. Rev. Immunol. 2012, 12:253-268.
22. Hengel R.L., Jones B.M., Kennedy M.S., Hubbard M.R., McDougal J.S. Markers of lymphocyte homing distinguish CD4 T cell subsets that turn over in response to HIV-1 infection in humans. J. Immunol. 1999, 163:3539-3548.
23. Sánchez-Hernández C., Gutiérrez-Ortega A., Aguilar-León D., Hernández-Pando R., Gómez-Lim M., Gómez-García B. In vivo activity of plant-based interleukin-12 in the lung of Balb/c mouse. BMC Res. Notes 2010, 3:151.
24. Huizinga T.W.J., Keijsers V., Yanni G., Hall M., Ramage W., Lanchbury J., Pitzalis C., Drossaers-Bakker W.K., Westendorp R.G.J., Breedveld F.C., Panayi G., Verweij C.L. Are differences in interleukin 10 production associated with joint damage?. Rheumatology 2000, 39:1180-1188.
25. Lawichi S., Szmitkowski M., Wojtukiewicz M. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients. Clin. Chim. Acta 2006, 37:112-116.
26. Lortat-Jacob H., Baltzer F., Grimaud J.A. Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence. J. Biol. Chem. 1996, 271:16139-16143.
27. Kallio R., Surcel H.M., Bloigu A., Syrjälä H. Balance between interleukin-10 and interleukin-12 in adult cancer patients with or without infections. Eur. J. Cancer 2001, 37:857-861.
28. Keane J., Balcewicz-Sablinska M.K., Remold H.G., Chupp G.L., Meek B.B., Fenton M.J., Kornfeld H. Infection by Mycobacterium tuberculosis promotes human alveolar macrophage apoptosis. Infect. Immun. 1997, 65:298-304.
29. Kendall M.D. Dying to Live. How Our Bodies Fight Disease 1998, Cambridge University.
30. Kim Y., Lawler S., Nowicki M.O., Chiocca E.A., Friedman A. A mathematical model for pattern formation of glioma cells outside the tumor spheroid core. J. Theor. Biol. 2009, 260:359-371.
31. Kim Y., Wallace J., Li F., Ostrowski M., Friedman A. Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor. a mathematical model and experiments. J. Math. Biol. 2010, 61:401-421.
32. Kurzrock R., Rosenblum M.G., Sherwin S.A., Rios A., Talpaz M., Quesada J.R., Gutterman J.U. Pharmacokinetics, single-does tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res. 1985, 45:2866-2872.
33. Le T., Leung L., Carroll W.L., Schibler K.R. Regulation of interleukin-10 gene expression. possible mechanisms accounting for its upregulation and for maturational differences in its expression by blood mononuclear cells. Blood 1997, 89:4112-4119.
34. Lee S.M., Suen Y., Chang L., Bruner V., Qian J., Indes J., Knoppel E., van de Ven C., Cairo M.S. Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon-gamma, natural killer, and lymphokine-activated killer activity by IL-12 in cord blood mononuclear cells. Blood 1996, 88:945-954.
35. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine systems in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
36. Marino S., Kirschner D.E. The human immune response to Mycobacterium tuberculosis in lung and lymph node. J. Theor. Biol. 2004, 227:463-486.
37. Marino S., Hogue I.B., Ray C.J., Kirschner D.E. A methodology for performing global uncertainty and sensitivity analysis in systems biology. J. Theor. Biol. 2008, 254:178-196.
38. Moreaux J., Hose D., Reme T., Jourdan E., Hundemer M., Legouffe E., Moine P., Bourin P., Moos M., Corre J., et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006, 108:4194-4197.
39. Oren H., Duman N., Abacioglu H., Ozkan H., Irken G. Association between serum macrophage colony-stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates. Pediatrics 2001, 108:329-332.
40. Owen M.R., Sherratt J.A. Pattern formation and spatiotemporal irregularity in a model for macrophage tumor interactions. J. Theor. Biol. 1997, 189:63-80.
41. Owen M.R., Byrne H.M., Lewis C.E. Mathematical modeling of the use of macrophages as vehicles for drug delivery to hypoxic tumor sites. J. Theor. Biol. 2004, 226:377-391.
42. Plank M.J., Sleeman B.D., Jones P.F. A mathematical model of tumor angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins. J. Theor. Biol. 2004, 229:435-454.
43. Qian B., Deng Y., Hong Im J., Muschel R.J., Zou Y., Li J., Lang R.A., Pollard J.W. A distinct macrophage population mediated metastatic breast cancer cell extravasation, establishment and growth. PLoS One 2009, 4:e6563.
44. Robertson M.J., Ritz J. Interleukin 12. basic biology and potential applications in cancer treatment. Oncologist 1996, 1:88-97.
45. Roda J.M., Summer L.A., Evans R., Philips G.S., Marsh C.B., Eubank T.D. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J. Immunol. 2011, 187:1970-1976.
46. Kretz-Rommel A., Qin F., Dakappagari N., Ravey E.P., McWhirter J., Oltean D., Frederickson S., Maruyama T., Wild M.A., Nolan M.J., Wu D., Springhorn J., Bowdish K.S. CD200 expression on tumor cells immunotherapy approaches to cancer immunotherapy. J. Immunol. 2007, 178:5595-5605.
47. Rygiel T.P., Karnam G., Goverse G., van der Marel A.P., Greuter M.J., van Schaarenburg R.A., Visser W.F., Brenkman A.B., Molenaar R., Hoek R.M., Mebius R.E., Meyaard L. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor. Oncogene 2012, 24:2979-2988.
48. Rygiel T.P., Meyaard L. CD200R signalling in tumor tolerance and inflammation. a tricky balance. Curr. Opin. Immunol. 2012, 24:233-238.
49. Robertson M.J., Cameron C., Atkins M.B., Gordon M.S., Lotze M.T., Sherman M.L., Ritz J. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin. Cancer Res. 1999, 5:9-16.
50. Sachsenberg N., Perelson A.S., Yerly S., Schockmel G.A., Leduc D., Hirschel B., Perrin L. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J. Exp. Med. 1998, 187:1295-1303.
51. Schugart R.C., Friedman A., Zhao R., Sen C.K. Wound angiogenesis as a function of tissue oxygen tension. a mathematical model. Proc. Nat. Acad. Sci. 2008, 105:2628-2633.
52. Sickert D., Aust D.E., Langer S., Baretton G.B., Dieter P. Characterization of macrophage subpopulations and microvessel density in carcinomas of the gastrointestinal tract. Anticancer Res. 2007, 27:1693-1700.
53. Snelgove R.J., Goulding J., Didierlaurent A.M., Lyonga D., Vekaria S., Edwards L., Gwyer E., Sedgwick J.D., Barclay A.N., Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat. Immunol. 2008, 9:1074-1083.
54. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J. Leucocyte Biol. 2009, 86:1065-1073.
55. Sprent J., Basten A. Circulating T and B lymphocytes of the mouse. II. Lifespan. Cell Immunol. 1973, 7:40-59.
56. Sud D., Bigbee C., Flynn J.L., Kirschner D.E. Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. J. Immunol. 2006, 176:4296-4314.
57. Szomolay B., Eubank T.D., Roberts R.D., Marsh C.B., Friedman A. Modeling the inhibition of breast cancer growth by GM-CSF. J. Theor. Biol. 2012, 303:141-151.
58. Talebian F., Liu J.Q., Liu Z., Khattabi M., He Y., Ganju R., Bai X.F. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One 2012, 7:e31442.
59. Tang S., Liu H., Chen G., Rao Q., Geng Y., Zheng G., Zheng D., Wu K. Internalization and half-life of membrane-bound macrophage colony-simulating factor. Chin. Sci. Bull. 2000, 45:1697-1703.
60. Tonks A., Hills R., White P., Rosie B., Mills K.I., Burnett A.K., Darley R.L. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007, 21:566-568.
61. Utting J.C., Flanagan A.M., Brandao-Burch A., Orriss I.R., Aenett T.R. Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem. Funct. 2010, 28:374-380.
62. Vaupel P., Mayer A., Briest S., Höckel M. Oxygenation gain factor. a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res. 2003, 63:7634-7637.
63. Vesosky B., Flaherty D.K., Turner J. Th1 cytokines facilitate CD8-T-cell-mediated early resistance to infection with Mycobacterium tuberculosis in old mice. Infect. Immun. 2006, 74:3314-3324.
64. Vincensini D., Dedieu V., Eliat P.A., Vincent C., Bailly C., de Certaines J., Joeffre F. Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magn. Reson. Imaging 2007, 25:293-302.
65. Wang L., Liu J.Q., Talebian F., Ei-Omrani H.Y., Khattabi M., Yu L., Bai X.F. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur. J. Immunol. 2010, 40:2569-2579.
66. Wigginton J.E., Kirschner D. A model to predict cell-mediated immune regulatory mechanisms during human infection with Mycobacterium tuberculosis. J. Immunol. 2001, 166:1951-1967.
67. Winslow G.M., Roberts A.D., Blackman M.A., Woodland D.L. Persistence and turnover of antigen-specific CD4+ T cells during chronic tuberculosis infection in the mouse. J. Immunol. 2003, 170:2046-2052.
68. Wong K.K., Khatri I., Shaha S., Spaner D.E., Gorczynski R.M. The role of CD200 in immunity to B cell lymphoma. J. Leucocyte Biol. 2010, 88:361-372.
69. Zhang X., Niessner A., Nakajima T., Ma-Krupa W., Kopecky S.L., Frye R.L., Goronzy J.J., Weyand C.M. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ. Res. 2006, 98:524-531.
70. Zhou L., Nazarian A.A., Smale S.T. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol. Cell. Biol. 2004, 24:2385-2396.